Here is the short answer most peptide articles bury: the peptides with real, trial-grade weight-loss evidence are the GLP-1 medications you have already heard of, semaglutide and tirzepatide. They are peptides. Almost everything else marketed as a "weight-loss peptide" is either a supporting player (helpful for energy or body composition, not for driving the scale down) or an unproven, grey-market product you should approach with real caution. This guide sorts the field honestly so you can tell the difference.
Key takeaways
- GLP-1 medications are peptides. Semaglutide and tirzepatide are peptide molecules, and they are the only weight-loss peptides backed by large randomized trials.
- In clinical trials, the results are meaningful. Adults on semaglutide 2.4 mg lost about 15% of body weight over 68 weeks (STEP 1); adults on tirzepatide 15 mg lost about 21% over 72 weeks (SURMOUNT-1). Individual results vary and depend on the full program.
- "Support" peptides are not weight-loss drugs. Sermorelin, vitamin B12, and lipotropic injections may support energy, recovery, or body composition alongside a GLP-1, but they do not melt fat on their own.
- Be very careful with "research" peptides like BPC-157, CJC-1295, and ipamorelin. They are not FDA-approved, have no weight-loss evidence, and their compounding status was unsettled through 2026. Elara does not offer them.
- Only a licensed provider can tell you what's appropriate. Compounded medications are not FDA-approved. Talk to a clinician about your history, your goals, and your safety.
Wait, are GLP-1s actually peptides?
Yes. A peptide is simply a short chain of amino acids, the same building blocks that make up proteins. Your body uses peptides as signaling molecules, tiny messengers that tell your organs what to do.
GLP-1 (glucagon-like peptide-1) is one of those natural messengers. It's a gut hormone that rises after you eat and helps you feel full. Semaglutide and tirzepatide are lab-made peptides designed to act like it, they are "GLP-1 receptor agonists." Semaglutide targets the GLP-1 receptor; tirzepatide is a dual peptide that targets both GIP and GLP-1 receptors. Both work by turning up satiety, slowing how fast your stomach empties, and steadying blood sugar.
So when someone asks about "peptides for weight loss," the honest reframe is this: you're already asking about GLP-1s. They just happen to be the peptides with the science behind them.
Which peptides actually have weight-loss evidence?
Only two, and they are the GLP-1 medications.
- Semaglutide. In the STEP 1 trial, published in the New England Journal of Medicine in 2021, adults with overweight or obesity who took once-weekly semaglutide 2.4 mg alongside lifestyle support lost a mean of about 14.9% of their body weight over 68 weeks, compared with about 2.4% on placebo. [1]
- Tirzepatide. In the SURMOUNT-1 trial, published in NEJM in 2022, adults on the 15 mg dose lost a mean of about 20.9% over 72 weeks. [2] Across the trials, tirzepatide tends to produce greater average weight loss than semaglutide, which is consistent with its dual mechanism.
These are averages from clinical trials, not promises. Your outcome depends on your dose, your nutrition and activity, your hormones, and the full program around the medication. Frame it as a tool, not a guarantee.
A note on names, because it matters for compliance and for your safety: only Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes, using them for weight loss is off-label. And compounded semaglutide or tirzepatide, whatever the molecule inside, is not FDA-approved.
The honest peptide sorting table
| Peptide (or "peptide-adjacent") | What it actually is | Weight-loss evidence | FDA / legal status in 2026 | How to think about it |
|---|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist peptide | Strong, ~15% over 68 wks (STEP 1) [1] | Wegovy FDA-approved for weight loss; Ozempic diabetes-only (off-label for weight); compounded is not FDA-approved | The evidence-backed core |
| Tirzepatide | Dual GIP + GLP-1 peptide | Strong, ~21% over 72 wks (SURMOUNT-1) [2] | Zepbound FDA-approved for weight loss; Mounjaro diabetes-only (off-label for weight); compounded is not FDA-approved | The evidence-backed core |
| Sermorelin | Peptide that nudges your own pituitary (GHRH analog) | None for weight loss; may support body composition/recovery | Not FDA-approved in compounded form; can be compounded by licensed pharmacies | Supportive adjunct, with protein + resistance training |
| Vitamin B12 (Lipo-B) | A vitamin, not a peptide | None unless you're deficient | Prescription vitamin | Energy/deficiency support; common GLP-1 companion |
| Lipotropic / MIC | Amino acids + vitamins, not a peptide | Limited, low-quality; not proven to drive weight loss | Not FDA-approved for weight loss | Adjunct to diet, activity, or a GLP-1 |
| BPC-157, CJC-1295, ipamorelin | Peptides marketed for recovery/"anti-aging" | None for weight loss | Not FDA-approved; compounding status unsettled through 2026 (see below) | Not offered by Elara; avoid grey-market sellers |
The peptides that support the process (but don't drive weight loss)
These come up constantly in "peptide stack" marketing. Two of them aren't even peptides. All three are honest support, never a substitute for a GLP-1.
Sermorelin
Sermorelin is a growth-hormone-releasing peptide, it gently signals your own pituitary gland rather than acting as synthetic HGH. It is not a weight-loss drug, and compounded sermorelin is not FDA-approved and has no approved anti-aging or weight-loss indication. Where it can fit, honestly, is the muscle-and-recovery conversation: alongside adequate protein and resistance training, it's discussed as body-composition support, which matters because fast weight loss can cost you lean muscle. If that's your question, start with our guide to sermorelin for women.
Vitamin B12 injections
B12 is a vitamin, not a peptide, but it's bundled into so many "peptide" weight-loss packages that it belongs here. The straight answer: there's no evidence B12 causes weight loss unless you're actually deficient. Its real value is energy and correcting deficiency, and it's a sensible companion on a GLP-1, where reduced appetite can lower your intake. We break it down in B12 shots for weight loss.
Lipotropic and MIC injections
Lipotropic ("MIC") shots combine methionine, inositol, and choline, often with B vitamins. The ingredients play roles in fat metabolism, but the evidence that the injections cause meaningful weight loss on their own is limited and low-quality, and they are not FDA-approved for weight loss. They're best understood as an adjunct to nutrition, activity, or a GLP-1, some people find the B-vitamin component helps with energy. See do lipotropic / MIC injections work, and if you're already on a GLP-1, should you stack them with semaglutide.
The through-line: none of these are a weight-loss engine. They ride alongside the GLP-1; they don't replace it.
The peptides to be careful with: BPC-157, CJC-1295, ipamorelin & "research" peptides
If you've read forums or watched longevity podcasts, you've seen peptides like BPC-157, CJC-1295, ipamorelin, TB-500, and others promoted for healing, "anti-aging," or fat loss. Here's the grounded view.
There is no rigorous human evidence that these cause weight loss. They are not FDA-approved for weight loss, or for anything else you can buy over the counter.
Their compounding status has been a genuinely moving target, which is exactly why you should be cautious. In late 2023 the FDA placed 19 popular peptides, including BPC-157, CJC-1295, and ipamorelin, into a restricted "Category 2" bucket for bulk substances that "may present significant safety risks," which meant licensed pharmacies could not lawfully compound them; the FDA said it intended to take regulatory action against compounders who did. [3][4] Then in early 2026 the picture shifted: on February 27, 2026, HHS announced that roughly 14 of those 19 peptides would move back toward the compoundable "Category 1," with several under FDA advisory-committee review. [5] Crucially, as pharmacists were quick to note, coming off a restricted list is not FDA approval, it does not establish that a peptide is safe, effective, or correctly dosed for weight loss. [5]
Two practical takeaways:
- Elara does not offer BPC-157, CJC-1295, ipamorelin, or similar "research" peptides, and we don't recommend chasing them for weight loss.
- "Research use only" and "not for human consumption" are red flags, not loopholes. The FDA has warned that unapproved GLP-1 and peptide products sold this way skip the review for safety, effectiveness, and quality, and it has documented dosing errors, unapproved salt forms, adverse events requiring hospitalization, and outright counterfeits in this market. [8] If a seller offers injectable peptides with no prescription and no licensed provider, walk away.
Can you take peptides together with a GLP-1?
Sometimes, but it's a clinician's call, not a self-serve stack. The sensible combinations are supportive: B12 for energy or a documented deficiency, sermorelin for body composition alongside training, or a lipotropic shot as an adjunct. None of these should be positioned as a second weight-loss drug, and none should replace the GLP-1 that's doing the actual work.
The reason to keep a provider in the loop isn't red tape. It's that GLP-1s interact with other medications, your dose needs titrating, and your history, thyroid, gallbladder, pregnancy plans, PCOS, perimenopause, changes what's safe for you. A legitimate program reviews all of that before adding anything.
Are weight-loss peptides FDA-approved? The 2026 rules, explained
This is where a lot of marketing gets slippery, so here it is plainly.
- FDA-approved for weight loss: Wegovy (semaglutide) and Zepbound (tirzepatide). These went through the full FDA review.
- FDA-approved, but for diabetes: Ozempic (semaglutide) and Mounjaro (tirzepatide). Using them for weight loss is off-label.
- Not FDA-approved: all compounded semaglutide and tirzepatide, and every "research" peptide (BPC-157 and friends).
On compounding specifically, forget the old "it's available because of a shortage" story, that framing is stale and no longer true. The FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025, and the mass, shortage-based compounding that followed wound down in 2025. [6] What survives is narrow, patient-specific compounding under section 503A when a licensed clinician documents a genuine clinical need for an individual patient. And the ground is still shifting: on April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B "bulks" list, with a public comment period extended to July 30, 2026. That proposal is proposed, not final, it's worth watching, and any legitimate provider should be transparent about it. [7]
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.
One more reason accuracy matters here: regulators are actively policing this space. In December 2025 the FTC finalized an order against telehealth GLP-1 seller NextMed over deceptive marketing, fake testimonials, before-and-after images from people who never used the product, and hidden costs. [9] That's the environment. Honest, sourced information isn't just good manners; it's the standard you should hold any provider to.
What about safety, what should every woman know first?
Every FDA-approved GLP-1 carries a boxed warning, the FDA's most serious, for the risk of thyroid C-cell tumors seen in rodent studies. These medications are contraindicated if you or a close family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Other important cautions include pancreatitis, gallbladder problems, and significant nausea, vomiting, or diarrhea, especially while your dose is going up. GLP-1s are not recommended in pregnancy or breastfeeding. This is not the full list, read the FDA prescribing information for your specific medication, and talk to a licensed provider about your history before starting or combining anything. [11][12]
How Elara helps
Elara is a women's telehealth program built around the peptides that actually have the evidence: semaglutide and tirzepatide. A licensed provider reviews every patient, your history, your hormones, your goals, and prescribes only when it's appropriate for you. We serve all 50 states and Puerto Rico, on a simple cash-pay basis (no insurance hurdles, no denials).
The pricing is transparent and all-inclusive, the provider visit, the medication, shipping, ongoing access to our medical team, and the Elara app are all in one number:
| Program | Starts at | Lowest per-month (12-month plan) |
|---|---|---|
| Compounded semaglutide | $247/month | ~$198/month |
| Compounded tirzepatide | $355/month | ~$298/month |
For comparison, brand-name Wegovy lists at roughly $1,349/month. [10] We don't tell you it's "the same medication for less", that wouldn't be honest. We tell you the truth about price and access, and we're clear that compounded medications are not FDA-approved. Where a lower-risk support option like B12 or a lipotropic injection genuinely fits your plan, your provider can discuss it, as a supporting player, never a replacement for the GLP-1.
Start with Elara's free eligibility check, a licensed provider reviews every patient. You can also explore Elara's compounded semaglutide program or compounded tirzepatide program to see how each works.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.
Frequently asked questions
Are GLP-1s peptides?
Yes. Semaglutide and tirzepatide are peptide molecules, short chains of amino acids that act like your body's natural GLP-1 hormone. That's why "peptides for weight loss" and "GLP-1s" overlap: the GLP-1 medications are the weight-loss peptides with large, published clinical trials behind them.
What are the best peptides for weight loss?
The two with strong trial evidence are the GLP-1 medications: semaglutide (about 15% average loss over 68 weeks in STEP 1) and tirzepatide (about 21% over 72 weeks in SURMOUNT-1). Other "peptides" marketed for weight loss either play a supporting role or lack evidence. A licensed provider can help you choose.
Can you take peptides with a GLP-1?
Sometimes, but only under a clinician's guidance. Supportive options like vitamin B12 (for energy or deficiency), sermorelin (for body composition with training), or lipotropic injections may be added as adjuncts. None replaces the GLP-1, and your provider should review your full history before combining anything.
Are weight-loss peptides FDA-approved?
Only some. Wegovy and Zepbound are FDA-approved for weight loss; Ozempic and Mounjaro are approved for diabetes (weight loss is off-label). Compounded semaglutide and tirzepatide are not FDA-approved, and "research" peptides like BPC-157 are not FDA-approved for any use you can buy directly.
Is BPC-157 or CJC-1295 legal in 2026?
Their status has been unsettled. The FDA restricted them from compounding in late 2023 (Category 2), and in early 2026 several were moved back toward the compoundable list, but that is not FDA approval, and there is no weight-loss evidence for them. Elara does not offer them, and grey-market "research" sellers are a red flag.
The bottom line
If you're searching for "peptides for weight loss," you've already found the answer: the peptides that work are the GLP-1 medications, semaglutide and tirzepatide, and they work best inside a real program with a licensed provider. Support peptides and injections can ride along, but they don't drive the results, and the trendy "research" peptides don't have the evidence or the regulatory footing to earn your trust or your money.
References
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- U.S. Food & Drug Administration. "Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks." https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Frier Levitt. "Regulatory Status of Peptide Compounding in 2025." https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/
- Pharmacy Times. "The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means." https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means
- U.S. Food & Drug Administration. "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize." https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food & Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- U.S. Food & Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Federal Trade Commission. "FTC Approves Final Order Against Telehealth Provider NextMed Over Charges It Used Deceptive Advertising Claims to Sell GLP-1 Weight-Loss Programs" (Dec. 3, 2025). https://www.ftc.gov/news-events/news/press-releases/2025/12/ftc-approves-final-order-against-telehealth-provider-nextmed-over-charges-it-used-deceptive
- NovoCare. "Wegovy (semaglutide) Cost, Coverage, & Savings Resources." https://www.novocare.com/patient/medicines/wegovy.html
- DailyMed (U.S. National Library of Medicine). "WEGOVY- semaglutide injection, solution", FDA prescribing information (label). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564
- DailyMed (U.S. National Library of Medicine). "ZEPBOUND- tirzepatide injection, solution", FDA prescribing information (label). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
This article is for general education and is not medical advice. Talk to a licensed clinician about your situation.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.